Evidence map›Paper›PMID 33241036›Full record

ArticleAnnals of translational medicine2020

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Jinzhang Chen, Xiaoyun Hu, Qi Li, Wencong Dai, Xiao Cheng, Wei Huang, Wenxuan Yu, Mian Chen, Yabing Guo, Guosheng Yuan

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jinzhang ChenDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Xiaoyun HuDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Qi LiDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Wencong DaiDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Xiao ChengDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Wei HuangDepartment of Oncology, ShunDe Hospital, Southern Medical University, Guangzhou, China.
Wenxuan YuDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Mian ChenTransplant Immunology Laboratory, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Headington, Oxford, UK.
Yabing GuoDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Guosheng YuanDepartment of Infectious Diseases and Hepatology Unitl, Southern Medical University, Guangzhou, China.
Nanfang Hospital · CNSouthern Medical University · CNUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) patients in a real-life cohort.

methodsWe analysed hepatitis B virus (HBV)-associated HCC patients treated with toripalimab, camrelizumab, or sintilimab in a retrospective single-center cohort from November 2018 to June 2020. Efficacy was evaluated with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS). Safety data were also recorded.

resultsSeventy patients were finally included in the analysis: 23 were treated with toripalimab, 33 with camrelizumab, and 14 with sintilimab. The mean duration of follow-up was 44.7 (95% CI: 39.9-49.6) weeks and the mean cycles of PD-1 at cutoff were 8.3±8.0 for all patients. The ORR and DCR for the whole cohort were 30% and 72.9%, respectively. Overall, 25 (35.7%) patients had radiological disease progression and 10 (14.3%) patients died during follow-up. Median PFS, median TTP, and median OS had not yet been reached. Most frequent drug-related adverse events (AEs) were rash (27.1%), hypertension (18.6%), fatigue (17.1%), diarrhea (17.1%), paresthesia (15.7%), and nausea (15.7%).

conclusionsOur findings suggest that (I) PD-1 targeted immunotherapy with toripalimab, camrelizumab, or sintilimab yielded a promising outcome in Chinese HBV patients with HCC and that (II) immunotherapy was well tolerated generally and had manageable side effects. This approach thus warrants further popularization and application in clinical practice.

Indexed as

anti-programmed cell death protein-1 antibody (anti-PD-1 antibody)camrelizumabHepatocellular carcinoma (HCC)programmed death receptor-1sintilimabtoripalimab

Identifiers

PMID33241036
PMCPMC7576044
OpenAlexW3087717452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.